The Trump administration has thrown its support behind Bayer as the company urges the U.S. Supreme Court to review thousands of lawsuits alleging its Roundup weedkiller causes cancer. In a filing submitted by U.S. Solicitor General D. John Sauer, the administration argued that federal pesticide regulations should override state-level claims, reinforcing Bayer’s position that its product labels comply with long-established federal standards.
Bayer is seeking to overturn a lower court ruling that upheld a $1.25 million verdict for Missouri plaintiff John Durnell, who linked his non-Hodgkin’s lymphoma diagnosis to long-term Roundup exposure. The company currently faces more than 67,000 similar lawsuits nationwide. Bayer maintains that extensive scientific research and decades of Environmental Protection Agency (EPA) reviews show glyphosate—the active ingredient in Roundup—is safe when used as directed.
According to Sauer, allowing state courts to require different warning labels would undermine the EPA’s authority and lead to inconsistent regulatory standards. The EPA has repeatedly found that glyphosate is “not likely to be carcinogenic to humans,” and has approved labels without cancer warnings. Pro-business groups, including the U.S. Chamber of Commerce, also back Bayer, warning that upholding the ruling could expand liability for companies that comply with federal law.
Attorneys for Durnell urged the Supreme Court to reject Bayer’s appeal, arguing that the plaintiff relied not only on product labels but also on the company’s marketing, which failed to warn consumers of potential health risks.
Roundup remains one of the most widely used herbicides in the United States. While Bayer paid approximately $10 billion in 2020 to settle earlier claims, new lawsuits continue to emerge. The company has experienced mixed outcomes in court, including a massive $2.1 billion Georgia verdict that was later settled. As litigation intensifies, Bayer has warned that it may pull Roundup from the U.S. market and has already replaced glyphosate in consumer formulations with alternative weedkillers.


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Iran–U.S. Nuclear Talks in Oman Face Major Hurdles Amid Rising Regional Tensions
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Trump Says “Very Good Talks” Underway on Russia-Ukraine War as Peace Efforts Continue
U.S. to Begin Paying UN Dues as Financial Crisis Spurs Push for Reforms
Nighttime Shelling Causes Serious Damage in Russia’s Belgorod Region Near Ukraine Border
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



